Brii Biosciences Limited (2137) AI Stock Analysis

• Market Cap: €1.42B
• Dividend Yield: N/A
• Average Volume (3M): 9.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: N/A
• EPS Growth: -41.48%
• Country: HK
• Employees: 98
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 732,292,800
• 10 Day Avg. Volume: 12,062,950
• 30 Day Avg. Volume: 9,340,821
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.00
• Price Target Upside: 5.72% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 46 Neutral
• Price Target: HK$2.00 ▲(5.82% Upside)

Brii Biosciences faces significant financial challenges, with ongoing operational losses and negative cash flow trends posing risks to financial stability. Technical indicators suggest a bearish trend, and valuation metrics are unfavorable due to the negative P/E ratio. These factors collectively result in a low overall stock score.

Brii Biosciences Limited Business Overview & Revenue Model

Company Description

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

How the Company Makes Money

Brii Biosciences Limited generates revenue through the development and commercialization of pharmaceutical products aimed at treating infectious diseases. The company's revenue model includes licensing agreements, collaborative research and development partnerships, and milestone payments from its strategic partners. These collaborations often involve sharing the costs and risks associated with drug development, while enabling Brii Biosciences to receive royalties from the sales of successfully commercialized products. Additionally, the company may benefit from government grants and funding for research into infectious disease treatments, contributing to its overall earnings.

Brii Biosciences Limited Financial Statement Overview

Summary

Brii Biosciences shows a strong equity position with substantial cash reserves, but faces severe profitability and cash flow challenges. The net loss widened in 2024, and the company struggles with negative free cash flow and operational inefficiencies, highlighting potential financial instability.

Income Statement

Brii Biosciences has experienced fluctuating revenue trends with a decline from 2023 to 2024. The net loss widened significantly in 2024, indicating profitability challenges. Margins such as the Gross Profit Margin remain stable at 100%, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The company's balance sheet shows a strong equity position but also reveals a concerning debt-to-equity ratio due to negative equity in previous years. The equity ratio is favorable, indicating a well-capitalized company, though historical liabilities have been significant relative to assets.

Cash Flow

Cash flow analysis indicates consistent negative free cash flow, which suggests challenges in generating cash from operations. The lack of operating cash flow in 2024 highlights potential liquidity risks, though substantial cash reserves provide a buffer.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	54.29M	56.32M	51.63M	92.54M	82.22M
Gross Profit	54.29M	56.32M	51.63M	92.54M	82.22M
EBITDA	-392.51M	-168.20M	-503.58M	-602.80M	-890.79M
Net Income	-508.16M	-174.83M	-452.63M	-4.12B	-1.21B
Balance Sheet
Total Assets	2.71B	3.20B	3.39B	3.61B	1.27B
Cash, Cash Equivalents and Short-Term Investments	2.33B	2.66B	3.00B	3.35B	1.05B
Total Debt	28.02M	3.16M	12.66M	21.62M	28.33M
Total Liabilities	100.55M	125.87M	234.35M	300.44M	3.01B
Stockholders Equity	2.66B	3.12B	3.19B	3.34B	-1.74B
Cash Flow
Free Cash Flow	-376.12M	-643.62M	-635.57M	-880.49M	-403.72M
Operating Cash Flow	-372.89M	-594.01M	-496.28M	-879.46M	-403.72M
Investing Cash Flow	895.47M	-104.35M	-1.43B	-475.76M	-43.65M
Financing Cash Flow	-9.41M	-10.98M	-3.04M	3.23B	657.00M

Brii Biosciences Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.89
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2137, the sentiment is Neutral. The current price of 1.89 is below the 20-day moving average (MA) of 2.03, below the 50-day MA of 1.92, and above the 200-day MA of 1.65, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 2.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2137.

Brii Biosciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	71 Outperform	HK$1.68B	211.43	0.99%	―	9.41%	-32.69%
1244	56 Neutral	HK$2.05B	―	-21.22%	―	-31.34%	67.95%
2126	54 Neutral	HK$2.51B	―	-41.34%	―	-10.78%	24.88%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
2137	46 Neutral	€1.42B	―	-14.48%	―	―	-41.48%
67N0	―	€273.31M	―	-4.30%	―	―	―
2511	36 Underperform	HK$1.94B	―	-67.27%	―	―	47.42%

Brii Biosciences Limited Corporate Events

Brii Biosciences Partners with Joincare for BRII-693 Development in Greater China

Brii Biosciences Limited has entered into a licensing agreement with Joincare Pharmaceutical Group to develop and commercialize BRII-693, a novel antibiotic for multidrug-resistant infections, in Greater China. This partnership leverages Joincare’s expertise in manufacturing and commercialization, aiming to address the critical unmet clinical needs for hospital antibiotics in the region, thereby enhancing Brii Biosciences’ strategic positioning in the anti-infection market.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Announces AGM Results and Board Changes

Brii Biosciences Limited announced the results of its Annual General Meeting held on June 3, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements, re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors, which underscores the company’s stability and ongoing commitment to strong governance practices.

The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.

Brii Biosciences Reports Promising Phase 2 Results for HBV Treatment

Brii Biosciences Limited announced promising interim data from its Phase 2 ENSURE study, presented at the European Association for the Study of the Liver Congress 2025. The study evaluates the combination of elebsiran, an investigational siRNA, with pegylated interferon alpha (PEG-IFN α) in treating chronic hepatitis B virus (HBV) infection. Results showed that participants previously treated with BRII-179, a therapeutic vaccine, achieved faster and higher rates of hepatitis B surface antigen (HBsAg) seroclearance compared to those without prior treatment. This suggests that pre-treatment with BRII-179 may enhance immune response, potentially allowing for shorter treatment durations. The findings could significantly impact the treatment landscape for chronic HBV, offering a more effective and efficient therapeutic option for patients.